{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:45:18Z","timestamp":1783125918697,"version":"3.54.6"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T00:00:00Z","timestamp":1522195200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Ministry of Health, Labor, and Welfare, Japan","award":["Research on Measures for Intractable Disease H24-General-076"],"award-info":[{"award-number":["Research on Measures for Intractable Disease H24-General-076"]}]},{"name":"the Ministry of Health, Labor, and Welfare, Japan","award":["H-26-Gereral-068"],"award-info":[{"award-number":["H-26-Gereral-068"]}]},{"name":"the Japan Agency for Medical Research and Development","award":["15ek0109055h0202"],"award-info":[{"award-number":["15ek0109055h0202"]}]},{"name":"the Japan Agency for Medical Research and Development","award":["16ek0109055h0203"],"award-info":[{"award-number":["16ek0109055h0203"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12185-018-2444-0","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T09:55:14Z","timestamp":1522230914000},"page":"192-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study"],"prefix":"10.1007","volume":"108","author":[{"name":"On behalf of the Japan LCH Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9168-5409","authenticated-orcid":false,"given":"Akira","family":"Morimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shioda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuko","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Kitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Tsunematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsaku","family":"Imashuku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,28]]},"reference":[{"key":"2444_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/ped.12380","volume":"56","author":"A Morimoto","year":"2014","unstructured":"Morimoto A, Oh Y, Shioda Y, Kudo K, Imamura T. Recent advances in Langerhans cell histiocytosis. Pediatr Int. 2014;56:451\u201361.","journal-title":"Pediatr Int"},{"key":"2444_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.13247","volume":"169","author":"ML Berres","year":"2015","unstructured":"Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to histiocytosis X? Br J Haematol. 2015;169:3\u201313.","journal-title":"Br J Haematol"},{"key":"2444_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.21498","volume":"51","author":"A Guyot-Goubin","year":"2008","unstructured":"Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000\u20132004. Pediatr Blood Cancer. 2008;51:71\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/MPH.0000000000000054","volume":"36","author":"BE Kim","year":"2014","unstructured":"Kim BE, Koh KN, Suh JK, Im HJ, Song JS, Lee JW, et al. Clinical features and treatment outcomes of Langerhans cell histiocytosis: a nationwide survey from Korea histiocytosis working party. J Pediatr Hematol Oncol. 2014;36:125\u201333.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2444_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/pbc.20364","volume":"45","author":"RF Jubran","year":"2005","unstructured":"Jubran RF, Marachelian A, Dorey F, Malogolowkin M. Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005;45:37\u201342.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR6","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/pbc.21145","volume":"48","author":"D Pollono","year":"2007","unstructured":"Pollono D, Rey G, Latella A, Rosso D, Chantada G, Braier J. Reactivation and risk of sequelae in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007;48:696\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/pbc.20021","volume":"42","author":"R Haupt","year":"2004","unstructured":"Haupt R, Nanduri V, Calevo MG, Bernstrand C, Braier JL, Broadbent V, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004;42:438\u201344.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1055\/s-2000-9667","volume":"212","author":"M Minkov","year":"2000","unstructured":"Minkov M, Grois N, Heitger A, P\u00f6tschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000;212:139\u201344.","journal-title":"Klin Padiatr"},{"key":"2444_CR9","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1067\/mpd.2001.111331","volume":"138","author":"H Gadner","year":"2001","unstructured":"Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans\u2019 cell histiocytosis. J Pediatr. 2001;138:728\u201334.","journal-title":"J Pediatr"},{"key":"2444_CR10","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood-2007-08-106211","volume":"111","author":"H Gadner","year":"2008","unstructured":"Gadner H, Grois N, P\u00f6tschger U, Minkov M, Aric\u00f2 M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008;111:2556\u201362.","journal-title":"Blood"},{"key":"2444_CR11","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood-2012-09-455774","volume":"121","author":"H Gadner","year":"2013","unstructured":"Gadner H, Minkov M, Grois N, P\u00f6tschger U, Thiem E, Aric\u00f2 M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013;121:5006\u201314.","journal-title":"Blood"},{"key":"2444_CR12","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/cncr.21985","volume":"107","author":"A Morimoto","year":"2006","unstructured":"Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006;107:613\u20139.","journal-title":"Cancer"},{"key":"2444_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s12185-016-1993-3","volume":"104","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016;104:99\u2013109.","journal-title":"Int J Hematol"},{"key":"2444_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/mpo.1178","volume":"37","author":"C Titgemeyer","year":"2001","unstructured":"Titgemeyer C, Grois N, Minkov M, Flucher-Wolfram B, Gatterer-Menz I, Gadner H. Pattern and course of single-system disease in Langerhans cell histiocytosis data from the DAL-HX 83- and 90-study. Med Pediatr Oncol. 2001;37:108\u201314.","journal-title":"Med Pediatr Oncol"},{"key":"2444_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/pbc.24367","volume":"60","author":"R Haupt","year":"2013","unstructured":"Haupt R, Minkov M, Astigarraga I, Sch\u00e4fer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18\u00a0years. Pediatr Blood Cancer. 2013;60:175\u201384.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.11827","volume":"93","author":"S Imashuku","year":"2008","unstructured":"Imashuku S, Shioda Y, Kobayashi R, Hosoi G, Fujino H, Seto S, et al. Neurodegenerative central nervous system disease as late sequelae of Langerhans cell histiocytosis. Report from the Japan LCH Study Group. Haematologica. 2008;93:615\u20138.","journal-title":"Haematologica"},{"key":"2444_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jpeds.2010.03.001","volume":"156","author":"N Grois","year":"2010","unstructured":"Grois N, Fahrner B, Arceci RJ, Henter JI, McClain K, Lassmann H, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010;156:873\u201381.","journal-title":"J Pediatr"},{"key":"2444_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/pbc.20425","volume":"46","author":"N Grois","year":"2006","unstructured":"Grois N, P\u00f6tschger U, Prosch H, Minkov M, Arico M, Braier J, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006;46:228\u201333.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR19","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/pbc.21315","volume":"50","author":"A Morimoto","year":"2008","unstructured":"Morimoto A, Kobayashi R, Maeda M, Asami K, Bessho F, Imashuku S. Impact of reactivation on the sequelae of multi-system Langerhans cell histiocytosis patients. Pediatr Blood Cancer. 2008;50:931\u20132.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jpeds.2008.05.002","volume":"153","author":"M Minkov","year":"2008","unstructured":"Minkov M, Steiner M, P\u00f6tschger U, Aric\u00f2 M, Braier J, Donadieu J, et al. Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry. J Pediatr. 2008;153:700\u20135.","journal-title":"J Pediatr"},{"key":"2444_CR21","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/pbc.22703","volume":"56","author":"A Morimoto","year":"2001","unstructured":"Morimoto A, Shioda Y, Imamura T, Kanegane H, Sato T, Kudo K, et al. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer. 2001;56:110\u20135.","journal-title":"Pediatr Blood Cancer"},{"key":"2444_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/MPH.0000000000000781","volume":"39","author":"S Imashuku","year":"2017","unstructured":"Imashuku S, Shioda Y, Morimoto A. CNS-directed prophylactic approach to Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2017;39:321\u20132.","journal-title":"J Pediatr Hematol Oncol"},{"key":"2444_CR23","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamaoncol.2017.5029","volume":"4","author":"EL Diamond","year":"2018","unstructured":"Diamond EL, Subbiah V, Lockhart AC, Blay JY, Puzanov I, Chau I, et al. Vemurafenib for BRAF V600-mutant Erdheim\u2013Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384\u20138. \n                    https:\/\/doi.org\/10.1001\/jamaoncol.2017.5029\n                    \n                  .","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2444-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2444-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2444-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T20:38:16Z","timestamp":1553719096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2444-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,28]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2444"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2444-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,28]]},"assertion":[{"value":"8 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}